Effect of repeated three-monthly albendazole treatments on malaria and allergic disease

Conditions

Helminth and malaria parasitic diseases Infections and Infestations

Ivonne Martin, Maria Mardalena Martini Kaisar, Aprilianto E. Wiria, Firdaus Hamid, Yenny Djuardi et al. (12 authors)

Frontiers in Genetics2019-11-0630 citations

10.3389/fgene.2019.01028

Dynamic changes in human-gut microbiome in relation to a placebo-controlled anthelminthic trial in Indonesia

Ivonne Martin, Yenny Djuardi, Erliyani Sartono, Bruce A. Rosa, Taniawati Supali et al. (8 authors)

PLoS neglected tropical diseases2018-08-0952 citations

10.1371/journal.pntd.0006620

Epidemiology of Plasmodium infections in Flores Island, Indonesia using real-time PCR.

Kaisar MM, Supali T, Wiria AE, Hamid F, Wammes LJ, Sartono E, Luty AJ, Brienen EA, Yazdanbakhsh M, van Lieshout L, Verweij JJ.

2013-05-2420 citations

10.1186/1475-2875-12-169

The effect of three-monthly albendazole treatment on malarial parasitemia and allergy: a household-based cluster-randomized, double-blind, placebo-controlled trial.

Wiria AE, Hamid F, Wammes LJ, Kaisar MM, May L, Prasetyani MA, Wahyuni S, Djuardi Y, Ariawan I, Wibowo H, Lell B, Sauerwein R, Brice GT, Sutanto I, van Lieshout L, de Craen AJ, van Ree R, Verweij JJ, Tsonaka R, Houwing-Duistermaat JJ, Luty AJ, Sartono E, Supali T, Yazdanbakhsh M.

2013-03-1946 citations

10.1371/journal.pone.0057899

A longitudinal study of allergy and intestinal helminth infections in semi urban and rural areas of Flores, Indonesia (ImmunoSPIN Study).

Hamid F, Wiria AE, Wammes LJ, Kaisar MM, Lell B, Ariawan I, Uh HW, Wibowo H, Djuardi Y, Wahyuni S, Schot R, Verweij JJ, van Ree R, May L, Sartono E, Yazdanbakhsh M, Supali T.

2011-04-0125 citations

10.1186/1471-2334-11-83

Does treatment of intestinal helminth infections influence malaria? Background and methodology of a longitudinal study of clinical, parasitological and immunological parameters in Nangapanda, Flores, Indonesia (ImmunoSPIN Study).

Wiria AE, Prasetyani MA, Hamid F, Wammes LJ, Lell B, Ariawan I, Uh HW, Wibowo H, Djuardi Y, Wahyuni S, Sutanto I, May L, Luty AJ, Verweij JJ, Sartono E, Yazdanbakhsh M, Supali T.

2010-03-2579 citations

10.1186/1471-2334-10-77

Interventions

400 mg albendazole (oral) or matching placebo every three months for 2 years.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Both males and females 2. Age >=2 years. No upper age limit. 3. Those who have given informed consent

Exclusion criteria

Exclusion criteria: 1. History of chronic liver, heart or central nervous system (CNS) disease 2. Allergy to albendazole

Design outcomes

Primary

Measure	Time frame
1. Prevalence of malaria parasite, assessed throughout the study for 3 years 2. Infection with intestinal helminth before treatment and within 1, 2 and 3 years after start of treatment 3. Skin reactivity to allergens assessed before treatment and within 1, 2 and 3 years after start of treatment	—

Secondary

Measure	Time frame
Immune response to malaria and helminth antigens, assessed before albendazole treatment and within 1, 2 and 3 years after the start of treatment (with the last treatment given at least 2 months before immunological determination).	—

Countries

Indonesia

Outcome results

None listed